Academic Journal
A Retrospective Cohort Study of Hospitalised Patients With First-Episode Substance-Induced Psychosis and First-Episode Psychosis: Comparing Long-Acting Injectable Antipsychotic Use and Post-Discharge Outcomes.
| Τίτλος: | A Retrospective Cohort Study of Hospitalised Patients With First-Episode Substance-Induced Psychosis and First-Episode Psychosis: Comparing Long-Acting Injectable Antipsychotic Use and Post-Discharge Outcomes. |
|---|---|
| Συγγραφείς: | Eun JD; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA., Iles-Shih M; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA., Ren S; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA., Hallgren KA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA., Kuczynski A; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA. |
| Πηγή: | Early intervention in psychiatry [Early Interv Psychiatry] 2026 Sep; Vol. 20 (9), pp. e70250. |
| Τύπος έκδοσης: | Journal Article; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 101320027 Publication Model: Print Cited Medium: Internet ISSN: 1751-7893 (Electronic) Linking ISSN: 17517885 NLM ISO Abbreviation: Early Interv Psychiatry Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Carlton,VIC, Australia : Wiley-Blackwell |
| Ιατρικοί όροι (MeSH): | Antipsychotic Agents*/administration & dosage , Antipsychotic Agents*/therapeutic use , Psychoses, Substance-Induced*/drug therapy , Psychotic Disorders*/drug therapy, Hospitalization/statistics & numerical data ; Patient Discharge/statistics & numerical data ; Humans ; Retrospective Studies ; Female ; Adult ; Male ; Delayed-Action Preparations ; Young Adult ; Adolescent |
| Περίληψη: | Introduction: Clinicians may not recommend long-acting injectable antipsychotics (LAI-APs) for patients diagnosed with first-episode substance-induced psychosis (FESIP), despite the risk of transition from FESIP to schizophrenia and the effectiveness of LAI-AP in early psychosis. We compared LAI-AP use and post-discharge outcomes between patients with first-episode psychosis (FEP) and those with FESIP during their index psychiatric hospitalisation. Methods: We conducted a retrospective cohort study using electronic health record data from patients aged 18-39 who were discharged from inpatient psychiatry units at a public academic hospital between 2021 and 2024. Outcomes included administration of any LAI-AP during the index hospitalisation, documented recommendation of any LAI-AP, psychiatric rehospitalisation and emergency department (ED) encounters after discharge. Results: The cohort included 90 patients with FEP and 84 patients with FESIP. Only one (1.2%) patient with FESIP received an LAI-AP compared with 10 (11.1%) with FEP (OR = 0.10, 95% CI = 0.002-0.71); LAI-AP was recommended to one (1.2%) patient with FESIP compared with 30 (33.3%) with FEP (OR = 0.02, 95% CI = 0.0006-0.16). Rehospitalisation occurred in 41 (45.6%) patients with FEP and 38 (45.2%) with FESIP; post-discharge ED encounters occurred in 50 (55.6%) and 52 (61.9%) patients, respectively. Time to first rehospitalisation and ED encounter after discharge did not differ between the groups. Conclusions: Despite similar post-discharge outcomes between patients with FEP and FESIP, administration or recommendation of an LAI-AP was rarer among those with FESIP. Our findings highlight uncertainty in treatment decision-making and support further research to guide early intervention strategies in patients with substance-induced psychosis. (© 2026 The Author(s). Early Intervention in Psychiatry published by John Wiley & Sons Australia, Ltd.) |
| References: | Abdel‐Baki, A., D. Thibault, S. Medrano, et al. 2020. “Long‐Acting Antipsychotic Medication as First‐Line Treatment of First‐Episode Psychosis With Comorbid Substance Use Disorder.” Early Intervention in Psychiatry 14, no. 1: 69–79. Addington, J., and D. Addington. 2007. “Patterns, Predictors and Impact of Substance Use in Early Psychosis: A Longitudinal Study.” Acta Psychiatrica Scandinavica 115, no. 4: 304–309. Brunette, M. F., K. T. Mueser, S. Babbin, et al. 2018. “Demographic and Clinical Correlates of Substance Use Disorders in First Episode Psychosis.” Schizophrenia Research 194: 4–12. Caton, C. L., R. E. Drake, D. S. Hasin, et al. 2005. “Differences Between Early‐Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance‐Induced Psychoses.” Archives of General Psychiatry 62, no. 2: 137–145. Chuenchom, O., T. Suansanae, L. Lukanapichonchut, S. Suwanmajo, and C. Suthisisang. 2024. “Real World Clinical Outcomes of Treatment of Cannabis‐Induced Psychosis and Prevalence of Cannabis‐Related Primary Psychosis: A Retrospective Study.” BMC Psychiatry 24, no. 1: 626. Denissoff, A., H. Taipale, J. Tiihonen, et al. 2024. “Antipsychotic Use and Psychiatric Hospitalization in First‐Episode Non‐Affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.” Schizophrenia Bulletin 50, no. 6: 1287–1294. Farnia, V., J. Shakeri, F. Tatari, et al. 2014. “Randomized Controlled Trial of Aripiprazole Versus Risperidone for the Treatment of Amphetamine‐Induced Psychosis.” American Journal of Drug and Alcohol Abuse 40, no. 1: 10–15. Inchausti, L., I. Gorostiza, M. A. Gonzalez Torres, and R. Oraa. 2023. “The Transition to Schizophrenia Spectrum Disorder From a First Psychotic Episode That Did or Did Not Appear to Be Induced by Substance Use.” Psychiatry Research 328: 115475. Iyer, S., N. Banks, M. A. Roy, et al. 2013. “A Qualitative Study of Experiences With and Perceptions Regarding Long‐Acting Injectable Antipsychotics: Part II‐Physician Perspectives.” Canadian Journal of Psychiatry 58, no. 5 Suppl 1: 23s–29s. Kane, J. M., N. R. Schooler, P. Marcy, et al. 2020. “Effect of Long‐Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early‐Phase Schizophrenia: A Randomized Clinical Trial.” JAMA Psychiatry 77, no. 12: 1217–1224. McCutcheon, R. A., T. Pillinger, I. Varvari, et al. 2025. “INTEGRATE: International Guidelines for the Algorithmic Treatment of Schizophrenia.” Lancet Psychiatry 12, no. 5: 384–394. Murrie, B., J. Lappin, M. Large, and G. Sara. 2020. “Transition of Substance‐Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta‐Analysis.” Schizophrenia Bulletin 46, no. 3: 505–516. Mustonen, A., H. Taipale, A. Denissoff, et al. 2025. “Real‐World Effectiveness of Antipsychotic Medication in Relapse Prevention After Cannabis‐Induced Psychosis.” British Journal of Psychiatry 228: 1–7. Potkin, S., R. Bera, D. Zubek, and G. Lau. 2013. “Patient and Prescriber Perspectives on Long‐Acting Injectable (LAI) Antipsychotics and Analysis of In‐Office Discussion Regarding LAI Treatment for Schizophrenia.” BMC Psychiatry 13: 261. R Core Team. 2024. “R: A Language and Environment for Statistical Computing (Version 4.4.2) [Computer software].” R Foundation for Statistical Computing. https://www.R‐project.org/. Rognli, E. B., I. H. Heiberg, B. K. Jacobsen, A. Høye, and J. G. Bramness. 2023. “Transition From Substance‐Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder.” American Journal of Psychiatry 180, no. 6: 437–444. Rognli, E. B., H. Taipale, C. Hjorthøj, et al. 2023. “Annual Incidence of Substance‐Induced Psychoses in Scandinavia From 2000 to 2016.” Psychological Medicine 53, no. 11: 5246–5255. Schoeler, T., N. Petros, M. Di Forti, et al. 2017. “Poor Medication Adherence and Risk of Relapse Associated With Continued Cannabis Use in Patients With First‐Episode Psychosis: A Prospective Analysis.” Lancet Psychiatry 4, no. 8: 627–633. Tiihonen, J., A. Tanskanen, and H. Taipale. 2018. “20‐Year Nationwide Follow‐Up Study on Discontinuation of Antipsychotic Treatment in First‐Episode Schizophrenia.” American Journal of Psychiatry 175, no. 8: 765–773. |
| Grant Information: | UW Medicine Garvey Institute for Brain Health Solutions |
| Contributed Indexing: | Keywords: antipsychotics; first‐episode psychosis; hospitalisation; long‐acting injectable; substance use; substance‐induced psychoses |
| Substance Nomenclature: | 0 (Antipsychotic Agents) 0 (Delayed-Action Preparations) |
| Entry Date(s): | Date Created: 20260921 Date Completed: 20260921 Latest Revision: 20260923 |
| Update Code: | 20260923 |
| PubMed Central ID: | PMC13591287 |
| DOI: | 10.1111/eip.70250 |
| PMID: | 42765189 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!